Patients Jobs About Novo Nordisk Contact information Finland | Media Research and development Responsible business 12 Prev Next front page / Patients Patients Diabetes Hemophilia Growth hormone Menopause Products Injection equipment For a Finnish patient Novo Nordisk has focused on developing drug treatment and services in four therapeutic areas: diabetes, hemophilia, growth hormone deficiency and menopausal replacement therapy. Use the links below to find out more about these therapy areas. For our prescription drugs, you will only find the information in the package leaflet on our page . If you use Novo Nordisk products and have any questions about them, please contact novoInfo . Diabetes With diabetes, it is possible to live an active and full life by taking good care of it. Read more Hemophilia Hemophilia is a rare bleeding disorder that only affects men Read more Growth hormone Growth hormone has many important functions in the human body. Read more Menopause Menopause is a normal era in every woman’s life, but they don’t have to degrade their quality of life. Read more Who are we The Danish company Novo Nordisk is a global pharmaceutical company with more than 90 years of experience as a pioneer in the development of diabetes care. The company is also a leader in the development of hemophilia treatment, growth hormone therapy and menopausal hormone therapy. Novo Nordisk has approximately 41,400 employees (June 2017) in 77 different countries and its products are marketed in more than 165 countries. Novo Nordisk A / S novonordisk.com Or select: other sites Novo Nordisk worldwide Map and addresses Facebook © Novo Nordisk A / S 2017 Disclaimer and Privacy